Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

v3.19.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2019
Accounting Policies [Abstract]  
Schedule of fair value on a nonrecurring basis
    Quoted Price in Active Markets for Identical Assets (Level 1)     Significant Other Observable Inputs (Level 2)     Significant Unobservable Inputs
(Level 3)
    Balance at
March 31, 2019
    Impairment
Loss
 
Patents and other technologies   $ -     $ -     $ 1,173,796     $ 1,173,796     $     -  

 

 

    Quoted Price in Active Markets for Identical Assets (Level 1)     Significant Other Observable Inputs (Level 2)     Significant Unobservable Inputs
(Level 3)
    Balance at December 31,
2018
    Impairment
Loss
 
Patents and other technologies   $ -     $ -     $ 1,255,689     $ 1,255,689     $     -  
Schedule of cash balances by geographic area
Country:   March 31, 2019     December 31, 2018  
United States   $ 955,125       54.0 %   $ 1,035,802       46.0 %
China     814,166       46.0 %     1,216,485       54.0 %
Total cash   $ 1,769,291       100.0 %   $ 2,252,287       100.0 %
Schedule of reconciliation of basic and diluted net loss per share
    Three Months Ended
March 31, 2019
    Three Months Ended
March 31, 2018
 
Net loss available to Avalon GloboCare Corp. common shareholders for basic and diluted net loss per share of common stock   $ (4,405,816 )   $ (1,481,579 )
Weighted average common stock outstanding - basic and diluted     73,690,461       69,781,733  
Net loss per common share attributable to Avalon GloboCare Corp. common shareholders - basic and diluted   $ (0.06 )   $ (0.02 )
Schedule of the effect of including these potential shares was antidilutive
    Three Months Ended
March 31, 2019
    Three Months Ended
March 31, 2018
 
Stock options     5,040,000       2,410,000  
Warrants     578,891       -  
Potentially dilutive securities     5,618,891       2,410,000